维生素D补充改善了接受新辅助化疗的乳腺癌患者的病理完整反应:一项随机临床试验
Michelle Sako Omodei1, Jackeline Chimicoviaki1, Daniel Araujo Brito Buttros1
1Graduate Program in Tocogynecology, Botucatu Medical School, Sao Paulo State University - UNESP, Botucatu, Sao Paulo, Brazil.
维生素D (VD) 补充剂在接受新辅助化疗 (NCT) 的乳腺癌 (BC) 妇女中显著增加了病理完整反应 (pCR) 率. 与安慰剂相比,每天2000IU的VD改善了PCR,这表明它在BC治疗中起着有益的作用.
科学领域:
- 在瘤学瘤学.
- 内分泌学 在内分泌学.
- 营养科学 营养科学
背景情况:
- 维生素D (VD) 缺乏症在乳腺癌 (BC) 患者中很常见.
- 在改善接受新辅助化疗 (NCT) 的BC治疗结果方面,VD补充的作用需要进一步研究.
研究的目的:
- 为了评估每天2000IU维生素D (胆卡西费醇) 补充剂对接受新辅助化疗的乳腺癌妇女病理完整反应 (pCR) 率的影响.
- 评估VD补充剂在NCT期间对血清25-基维生素-D [25(OH) D]水平的影响.
主要方法:
- 一项随机临床试验,涉及80名年龄≥45岁的女性,BC符合NCT的条件.
- 参与者被随机分配,每天接受2,000IU的VD (n=40) 或安慰剂 (n=40) 6个月.
- 主要结局是pCR率;在基线和NCT后测量了血清25(OH) D水平.
主要成果:
- 6个月后,与安慰剂相比,VD组的血清25(OH) D水平显著增加 (28 ± 8.7对比20.2 ± 6.1 ng/mL,p=0.03).
- 与安慰剂组 (24%,p=0.04) 相比,VD组中的pCR率 (43%) 显著更高.
- 较高的基线25(OH) D水平 (≥20ng/mL) 与实现pCR的可能性更高有关 (OR3.65,p=0.04).
结论:
- 每日补充2000IU维生素D可提高乳腺癌妇女接受新辅助化疗的病理完整反应率.
- 维生素D补充剂可能是接受新辅助化疗的乳腺癌患者的有益辅助疗法,特别是那些基线维生素D水平较低的患者.
更多相关视频
08:29Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
Published on: October 2, 2014
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
